Vagus nerve stimulation reduced inflammation and restored cognitive function after injury
For adults over age 65, surgical complications can dampen not only their physical health but also their mental sharpness, with more than half of high-risk cases declining into delirium.
In research published this week in the journal Brain Stimulation, Duke University scientists show in a mouse model that a current treatment for seizures can also reverse brain inflammation, such as inflammation after surgery, and the subsequent confusion or cognitive decline that results.
The therapy involves minimally invasive stimulation of the vagus nerve using small electrical pulses comparable to a cell phone’s vibrations.
The scientists used a Doppler ultrasound to guide the placement of a needle that delivers the electrical pulse, avoiding nearby delicate structures such as the carotid artery. Researchers hope to refine the technique into a completely non-invasive approach to preventing cognitive decline when seniors and other at-risk patients have surgery.
“Delirium is now recognized as the most common complication in older adults after surgery,” said Niccolò Terrando, Ph.D., associate professor of anesthesiology at Duke and the study’s senior author. “For most patients, it lasts a few days and resolves on its own. For some, it can lead to severe complications and even contribute to long lasting cognitive deficits, like dementia.”
Terrando noted that these cognitive complications have a huge impact on quality of life and can be expensive, with health care costs for delirium reaching $164 billion a year according to the American Society of Anesthesiologists.
“So far, there is no therapy for this kind of cognitive complication after surgery,” Terrando said. Anti-inflammatory drugs have many side effects and work broadly, he said, and they don’t adequately target the inflammation in the brain that scientists believe triggers cognitive complications.
The vagus nerve helps the brain communicate with the heart, lungs, gut and other parts of the body. Vagus nerve stimulators have been surgically implanted in epilepsy patients for more than 20 years to reduce seizures.
In recent years, U.S. doctors have also prescribed at-home, non-invasive stimulators for severe headaches. However, there is not substantial evidence that the devices are stimulating the vagus nerve and not other structures near it, said Warren M. Grill, Ph.D., professor of biomedical engineering at Duke.
For the experimental model, mice with inflammation received one nerve-stimulating treatment lasting several minutes. The researchers monitored for signs of vagus nerve activation, such as a slower heart rate and twitching of muscles around the larynx, and found improved cognitive outcomes and reduced brain inflammation after this treatment.
“This minimally invasive approach is already exceedingly benign, but in the long term it would be desirable to have an entirely non-invasive approach and we are beginning that work,” Grill said.
The Latest on: Vagus nerve stimulation
via Google News
The Latest on: Vagus nerve stimulation
- Neurostimulation Devices Market 2020 Research Report, Growth, Industry Analysis, Share, Trends Forecast to 2025on February 27, 2020 at 10:55 pm
Neurostimulation Devices Market by Top Key International Players Medtronic, Abbott, Boston Scientific, Cyberonics, Inc., biocontrol systems, inc., Synapse Biomedical, Nevro Forecast to 2026 Increasing ...
- Vagus Nerve Stimulators Market Innovative Solutions By Top Key Players BioControl Medical, Boston Scientific Corporation, CerboMed GmbHon February 27, 2020 at 4:31 pm
Global Vagus Nerve Stimulators Market 2020-2025 research report is an in-depth analysis of the latest trends, market size, status, upcoming technologies, industry drivers, challenges with key company ...
- Livanova teams up with Verily on depression trialon February 27, 2020 at 3:46 pm
The study, which kicked off last September, is assessing the effectiveness of vagus nerve stimulation (VNS) therapy for patients with difficult-to-treat depression (DTD). Meanwhile, Livanova ...
- LivaNova adds Verily to depression studyon February 27, 2020 at 9:49 am
LivaNova (NSDQ:LIVN) announced that it has added Google’s (NSDQ:GOOGL) Verily to its study of vagus nerve stimulation (VNS) therapy for difficult-to-treat depression (DTD). The Recover clinical will ...
- LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depressionon February 26, 2020 at 1:44 pm
LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a research collaboration with Verily, an Alphabet company, to capture ...
- Improved Mood and Remission of Symptoms in Long-term Major Depression Using Vagus Nerve Stimulationon February 20, 2020 at 4:00 pm
J.F. is a 68-year-old married white woman with a 32-year history of treatment-resistant MDD. Her early treatment included ineffectual trials of tricyclic antidepressants, serotonin reuptake ...
- Patient Experience With Non-Invasive Vagus Nerve Stimulator: gammaCore Patient Registryon February 19, 2020 at 1:10 pm
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better. Attacks fulfilling criteria for 3.1 Cluster headache and ...
- The Future of the Vagus Nerve Stimulators Market, 2020on February 18, 2020 at 3:13 am
No significant US FDA approval for the Vagus Nerve Stimulator has been recorded in 2019. In October 2018, Electrocore has received the US FDA approval for its non-invasive vagus nerve stimulator ...
- The Future of the Vagus Nerve Stimulators Market, 2020on February 18, 2020 at 2:33 am
Dublin, Feb. 18, 2020 (GLOBE NEWSWIRE) -- The "Vagus Nerve Stimulators Market 2019-2025" report has been added to ResearchAndMarkets.com's offering. The market is expected to grow in the near future ...
via Bing News